|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
|
31530568 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
L-THP suppressed the expression of miR-93 and increased the levels of PTEN, a crucial tumor suppressor in OC.
|
31128026 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
To explore the role of miR-200a combined with PTEN in the progression of ovarian carcinoma.
|
30024595 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The function of miR-222 was detected in ovarian carcinoma to verify the regulation of phosphatase and tensin homolog (PTEN) by miR-222. miR-222 expression in ovarian carcinoma tissues and cell lines were examined using RT-qPCR.
|
29963173 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>miR-216a</i> up-regulation is associated with cisplatin resistance in ovarian cancer and this effect is mediated by PTEN.
|
30061175 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, the results of dual-luciferase reporter assays indicated that PTEN was a direct downstream target of miR-19b in OC.
|
29963131 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Conditional homozygous knockout of PTEN mediated by PAX8-cre recombinase was sufficient to drive endometrioid and serous borderline ovarian carcinoma, providing the first model of FTE-derived borderline tumors.
|
29367766 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.
|
29142608 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overall, we suggest that miR-205 functions as an oncogenic miRNA by directly binding to SMAD4 and PTEN, providing a novel target for the molecular treatment of ovarian cancer.
|
28145479 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The OC tissues exhibited an increased expression of miR-214 and a reduced positive rate of PTEN expression compared with adjacent normal tissues. miR-214 may activate the PI3K/Akt signaling pathway by downregulating the targeted PTEN, which may promote OC cell proliferation and inhibit apoptosis.
|
29113199 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that although PTEN mutations in ovarian cancer are rare, PTEN inhibition results in therapeutic sensitization.
|
26905328 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
|
26212011 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of PTEN and TP53 were 0.21% and 0.53%, respectively, in the Southern Chinese patients with breast and/or ovarian cancers.
|
27157322 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Subcutaneously transplanted nude mice, as a model of human ovarian cancer, were used to test the effects of PTEN and KRT10 on cisplatin resistance of ovarian cancer in vivo.
|
26125866 |
2015 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN, a tumor suppressor gene, has been demonstrated to be able to reverse cisplatin-resistance in ovarian cancer cell line C13K.
|
24434152 |
2014 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway.
|
23408974 |
2013 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One patient exhibited mutations both in PIK3CA and PTEN at discordant sites between endometrial and ovarian carcinomas, whereas the other 4 exhibited concordant mutations.
|
22635024 |
2012 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
CTD_human |
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
|
21372221 |
2011 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrated that knockdown of miR-21 significantly increased the expression of PTEN, a known tumor suppressor in ovarian cancer.
|
21042775 |
2010 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine whether upregulation of PTEN gene by transfection wild-type PTEN gene to ovarian cancer cells can inhibit growth and migration and to explore the potential for PTEN gene therapy of ovarian cancers.
|
18662848 |
2008 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.
|
18199536 |
2008 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
|
17292821 |
2007 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN.
|
16551709 |
2006 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
|
16793127 |
2006 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that PTEN over-expression may represent a novel therapeutic approach for chemoresistant human ovarian cancer and that this may involve a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway.
|
16545436 |
2006 |